Description
Multimodality treatment for high-risk prostate cancer: New perspectives
- You cannot add another "Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer" to your cart. View cart
Article: Multimodality treatment for high-risk prostate cancer: New perspectives
€3.03
Related products
-
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€3.03 Add to cart -
Article: Highlights in genitourinary cancers
€3.03 Add to cart -
Article: Highlights in squamous cell carcinoma of the head and neck
€3.03 Add to cart -
Article: Highlights in breast cancer
€3.03 Add to cart
Reviews
There are no reviews yet.